The prognostic and predictive value of sstr-immunohistochemistry and sstr-targeted imaging in neuroendocrine tumors.
Purpose: Our aim was to assess the prognostic and predictive value of somatostatin receptor 2 (sstr) in neuroendocrine tumors (NETs). Methods: We established a tissue microarray and imaging database from NET patients that received sstr-targeted radiopeptide therapy with yttrium-90-DOTATOC, lutetium-...
| Publicado en: | European Journal of Nuclear Medicine & Molecular Imaging Vol. 44; no. 3; pp. 468 - 476 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Mar2017
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=121014869&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 121014869 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 16197070 NPC jtl: European Journal of Nuclear Medicine & Molecular Imaging issn: 16197070 maglogo: N pubinfo: dt: Mar2017 vid: 44 iid: 3 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 121014869 144098156 10.1007/s00259-016-3486-2 121014869 ppf: 468 ppct: 8 formats: fmt: @attributes: type: P tig: atl: The prognostic and predictive value of sstr-immunohistochemistry and sstr-targeted imaging in neuroendocrine tumors. aug: au: Brunner, Philippe Jörg, Ann-Catherine Glatz, Katharina Bubendorf, Lukas Radojewski, Piotr Umlauft, Maria Marincek, Nicolas Spanjol, Petar-Marko Krause, Thomas Dumont, Rebecca Maecke, Helmut Müller-Brand, Jan Briel, Matthias Schmitt, Anja Perren, Aurel Walter, Martin affil: Institute of Nuclear Medicine , University Hospital Basel , Basel Switzerland sug: ab: Purpose: Our aim was to assess the prognostic and predictive value of somatostatin receptor 2 (sstr) in neuroendocrine tumors (NETs). Methods: We established a tissue microarray and imaging database from NET patients that received sstr-targeted radiopeptide therapy with yttrium-90-DOTATOC, lutetium-177-DOTATOC or alternative treatment. We used univariate and multivariate analyses to identify prognostic and predictive markers for overall survival, including sstr-imaging and sstr-immunohistochemistry. Results: We included a total of 279 patients. In these patients, sstr-immunohistochemistry was an independent prognostic marker for overall survival (HR: 0.82, 95 % CI: 0.67 - 0.99, n = 279, p = 0.037). In DOTATOC patients, sstr-expression on immunohistochemistry correlated with tumor uptake on sstr-imaging ( n = 170, p < 0.001); however, sstr-imaging showed a higher prognostic accuracy (positive predictive value: +27 %, 95 % CI: 3 - 56 %, p = 0.025). Sstr-expression did not predict a benefit of DOTATOC over alternative treatment ( p = 0.93). Conclusions: Our results suggest sstr as an independent prognostic marker in NETs. Sstr-immunohistochemistry correlates with sstr-imaging; however, sstr-imaging is more accurate for determining the individual prognosis. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|